Influence of lifting prescribing restrictions for losartan on subsequent sartan utilization patterns in Austria: Implications for other countries

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 12, Issue 6, 2012, Pages 809-819

  Bucsics, Anna ^a   Godman, Brian ^b,c,d   Burkhardt, Thomas ^a   Schmitzer, Manuela ^a   Malmström, Rickard E ^b  

^a Hauptverband der Österreichischen Sozialversicherungsträger ^*  (Austria)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^d UNIVERSITY OF LIVERPOOL MANAGEMENT SCHOOL   (United Kingdom)

Author keywords

angiotensin receptor blockers; Austria; drug utilization studies; generics; losartan; prescribing restrictions

Indexed keywords

AMLODIPINE PLUS HYDROCHLOROTHIAZIDE PLUS OLMESARTAN; AMLODIPINE PLUS HYDROCHLOROTHIAZIDE PLUS VALSARTAN; AMLODIPINE PLUS OLMESARTAN; AMLODIPINE PLUS TELMISARTAN; ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; DIURETIC AGENT; EPROSARTAN; GENERIC DRUG; LOSARTAN; OLMESARTAN; TELMISARTAN; VALSARTAN;

AMBULATORY CARE; AUSTRIA; CONTROLLED STUDY; DRUG COST; DRUG FORMULATION; DRUG INDICATION; DRUG MARKETING; DRUG UTILIZATION; EUROPE; FIXED DOSE COMBINATION; HEALTH CARE COST; HUMAN; MAINTENANCE DRUG DOSE; PATENT; PRESCRIPTION; QUASI EXPERIMENTAL STUDY; REVIEW;

ADULT; AMBULATORY CARE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; AUSTRIA; DRUG COMBINATIONS; DRUG COSTS; DRUGS, GENERIC; HUMANS; LOSARTAN; PATENTS AS TOPIC; PHYSICIAN'S PRACTICE PATTERNS;

EID: 84871494431     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/erp.12.71     Document Type: Review

References (49)

1. Godman B, Bucsics A, Burkhardt T, Haycox A, Seyfried H, Wieninger P. Insight into recent reforms and initiatives in Austria: Implications for key stakeholders. Expert Rev. Pharmacoecon. Outcomes Res. 8(4), 357-371 (2008
2. Sermet C, Andrieu V, Godman B, Van Ganse E, Haycox A, Reynier JP. Ongoing pharmaceutical reforms in France: Implications for key stakeholder groups. Appl. Health Econ. Health Policy 8(1), 7-24 (2010
3. Wettermark B, Godman B, Andersson K, Gustafsson LL, Haycox A, Bertele V. Recent national and regional drug reforms in Sweden: Implications for pharmaceutical companies in Europe. Pharmacoeconomics 26(7), 537-550 (2008
4. Godman B, Wettermark B, Hoffmann M, Andersson K, Haycox A, Gustafsson LL. Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: Global relevance. Expert Rev. Pharmacoecon. Outcomes Res. 9(1), 65-83 (2009
5. Cameron A, Ewen M, Ross-Degnan D, Ball D, Laing R. Medicine prices, availability, and affordability in 36 developing and middle-income countries: A secondary analysis. Lancet 373(9659), 240-249 (2009
6. Garattini S, Bertele' V, Godman B, Haycox A, Wettermark B, Gustafsson LL; Piperska Group. Enhancing the rational use of new medicines across European health care systems. Eur. J. Clin. Pharmacol. 64(12), 1137-1138 (2008
7. Godman B, Shrank W, Wettermark B, Andersen M, Bishop I et al. Use of generics-a critical cost containment measure for all healthcare professionals in Europe? Pharmaceuticals 3, 2470-2494 (2010
8. Godman B, Shrank W, Andersen M et al. Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: Changes seen and lobal implications. Expert Rev. Pharmacoecon. Outcomes Res. 10(6), 707-722 (2010
9. Godman B, Shrank W, Andersen M et al. Policies to enhance prescribing efficiency in Europe: Findings and future implications. Frontiers Pharmacol. 1(141), 1-16 (2011
10. Godman B, Haycox A, Schwabe U, Joppi R, Garattini S. Having your cake and eating it: Office of fair trading proposal for funding new drugs to benefit patients and innovative companies. Pharmacoeconomics 26(2), 91-98 (2008
11. Godman B, Wettermark B, Bishop I, et al. European payer initiatives to reduce prescribing costs through use of generics. GABI 1, 22-27 (2012
12. Voncina L, Strizrep T, Godman B et al. Influence of demand-side measures to enhance renin-angiotensin prescribing efficiency in Europe: Implications for the future. Expert Rev. Pharmacoecon. Outcomes Res. 11(4), 469-479 (2011
13. Garuoliene K, Godman B, Gulbinovic J, Wettermark B, Haycox A. European countries with small populations can obtain low prices for drugs: Lithuania as a case history. Expert Rev. Pharmacoecon. Outcomes Res. 11(3), 343-349 (2011
14. McGinn D, Godman B, Lonsdale J, Way R, Wettermark B, Haycox A. Initiatives to enhance the quality and efficiency of statin and PPI prescribing in the UK: Impact and implications. Expert Rev. Pharmacoecon. Outcomes Res. 10(1), 73-85 (2010
15. Bennie M, Godman B, Bishop I, Campbell S. Multiple initiatives continue to enhance the prescribing efficiency for the proton pump inhibitors and statins in Scotland. Expert Rev. Pharmacoecon. Outcomes Res. 12(1), 125-130 (2012
16. Dylst P, Vulto A, Simoens S. The impact of reference-pricing systems in Europe: A literature review and case studies. Expert Rev. Pharmacoecon. Outcomes Res. 11(6), 729-737 (2011
17. Simoens S. A review of generic medicine pricing in Europe. GaBI 1, 8-12 (2012
18. Godman B, Abuelkhair M, Vitry A, et al. Payers endorse generics to enhance prescribing efficiency; impact and future implications, a case history approach. GABI 1(2), 21-35 (2012
19. Godman B, Malmstrom RE, Bennie M et al. Prescribing restrictions-a necessary strategy among some European countries to enhance future prescribing efficiency? Rev. Health Care 3, 5-16 (2012
20. Godman B, Burkhardt T, Bucsics A, Wettermark B, Wieninger P. Impact of recent reforms in Austria on utilization and expenditure of PPIs and lipid-lowering drugs: Implications for the future. Expert Rev. Pharmacoecon. Outcomes Res. 9(5), 475-484 (2009
21. Godman B, Bucsics A, Burkhardt T, Schmitzer M, Wettermark B, Wieninger P. Initiatives to enhance renin-angiotensin prescribing efficiency in Austria: Impact and implications for other countries. Expert Rev. Pharmacoecon. Outcomes Res. 10(2), 199-207 (2010
22. Godman B, Sakshaug S, Berg C, Wettermark B, Haycox A. Combination of prescribing restrictions and policies to engineer low prices to reduce reimbursement costs. Expert Rev. Pharmacoecon. Outcomes Res. 11(1), 121-129 (2011
23. Coma A, Zara C, Godman B et al. Policies to enhance the efficiency of prescribing in the Spanish Catalan region: Impact and future direction. Expert Rev. Pharmacoecon. Outcomes Res. 9(6), 569-581 (2009
24. Wettermark B, Godman B, Neovius M, Hedberg N, Mellgren TO, Kahan T. Initial effects of a reimbursement restriction to improve the cost-effectiveness of antihypertensive treatment. Health Policy 94(3), 221-229 (2010
25. Gustafsson LL, Wettermark B, Godman B et al.; Regional Drug Expert Consortium. The 'wise list'-a comprehensive concept to select, communicate and achieve adherence to recommendations of essential drugs in ambulatory care in Stockholm. Basic Clin. Pharmacol. Toxicol. 108(4), 224-233 (2011
26. Godman B, Paterson K, Malmstrom R et al. Improving the managed entry of new medicines: Sharing experiences across Europe Expert Rev. Pharmacoecon. Outcomes Res. 12(4),439-441(2012
27. Markovic-Pekovic V, Ranko Škrbić R, Godman B, Gustafsson LL. Ongoing initiatives in the Republic of Srpska to enhance prescribing efficiency: Influence and future directionse Expert Rev. Pharmacoecon. Outcomes Res. 12(5), 661-671 (2012
28. Fletcher AE, Palmer AJ, Bulpitt CJ Cough with angiotensin converting enzyme inhibitors: How much of a problem? J. Hypertens. Suppl. 12(2), S43-S47 (1994
29. Frisk P, Mellgren TO, Hedberg N, Berlin A, Granath F, Wettermark B. Utilisation of angiotensin receptor blockers in Sweden: Combining survey and register data to study adherence to prescribing guidelines. Eur. J. Clin. Pharmacol. 64(12), 1223-1229 (2008
30. Elliot H. Focus on the ONTARGET results. J. Hypertens. 27, S8-S10 (2009
31. McDowell SE, Coleman JJ, Ferner RE. Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine. BMJ 332(7551), 1177-1181 (2006
32. Moon J, Flett A, Godman B, Grosso A, Wierzbicki A. Getting better value from the NHS drug budget. BMJ 342, 30-32 (2011
33. Heran BS, Wong MM, Heran IK, Wright JM. Blood pressure lowering efficacy of angiotensin receptor blockers for primary hypertension. Cochrane Database Syst. Rev. 4, CD003822 (2008
34. Nixon RM, Müller E, Lowy A, Falvey H. Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: A meta-analytical approach. Int. J. Clin. Pract. 63(5), 766-775 (2009
35. Svanström H, Pasternak B, Hviid A. Association of treatment with losartan vs candesartan and mortality among patients with heart failure. JAMA 307(14), 1506-1512 (2012
36. Krum H. Optimising management of chronic heart failure. Lancet 374(9704), 1808-1809 (2009
37. Konstam MA, Neaton JD, Dickstein K et al.; HEAAL Investigators. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): A randomised, double-blind trial. Lancet 374(9704), 1840-1848 (2009
38. Usher-Smith J, Ramsbottom T,Pearmain H, Kirby M. Evaluation of the clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting: 2 years on. Int. J. Clin. Pract. 62(3), 480-484 (2008
39. Grimshaw J, Campbell M, Eccles M, Steen N. Experimental and quasi-experimental designs for evaluating guideline implementation strategies. Fam. Pract. 17(Suppl. 1), S11-S16 (2000
40. Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. J. Clin. Pharm. Ther. 27(4), 299-309 (2002
41. Vlahovic-Palcevski V, Gantumur M, Radosevic N, Palcevski G, Vander Stichele R. Coping with changes in the defined daily dose in a longitudinal drug consumption database. Pharm. World Sci. 32(2), 125-129 (2010
42. Spiegel W, Mlczoch-Czerny MT, Jens R, Dowrick C. Quality circles for pharmacotherapy to modify general practitioners' prescribing behaviour for generic drugs. J. Eval. Clin. Pract. 18(4), 828-834 (2012
43. Pettersson B, Hoffmann M, Wändell P, Levin LÅ. Utilization and costs of lipid modifying therapies following health technology assessment for the new reimbursement scheme in Sweden. Health Policy 104(1), 84-91 (2012
44. Godman B, Bennie M, Baumgärtel C, Sović Brkičić L et al. Essential to increase the use of generics in Europe to maintain comprehensive healthcare? Farmeconomia: Health Economics & Therapeutic Pathways (2012) (In Press
45. Sakshaug S, Furu K, Karlstad Ø, Rønning M, Skurtveit S. Switching statins in Norway after new reimbursement policy: A nationwide prescription study. Br. J. Clin. Pharmacol. 64(4), 476-481 (2007
46. Martikainen JE, Saastamoinen LK, Korhonen MJ, Enlund H, Helin-Salmivaara A. Impact of restricted reimbursement on the use of statins in Finland: A register-based study. Med. Care 48(9), 761-766 (2010
47. Wettermark B, Godman B, Jacobsson B, Haaijer-Ruskamp FM. Soft regulations in pharmaceutical policy making: An overview of current approaches and their consequences. Appl. Health Econ. Health Policy 7(3), 137-147 (2009
48. Bero LA, Grilli R, Grimshaw JM, Harvey E, Oxman AD, Thomson MA. Closing the gap between research and practice: An overview of systematic reviews of interventions to promote the implementation of research findings. The Cochrane Effective Practice and Organization of Care Review Group. BMJ 317(7156), 465-468 (1998
49. Barton S. Using clinical evidence. BMJ 322(7285), 503-504 (2001)